Zobrazeno 1 - 10
of 1 106
pro vyhledávání: '"Rajkumar SV"'
Autor:
Misund, Kristine, Keane, Niamh, Stein, Caleb, Asmann, Yan, Day, GM, Welsh, Seth, Van Wier, Scott, Riggs, Daniel, Ahmann, Gregory, Chesi, Marta, Viswanatha, DS, Kumar, SK, Dispenzieri, Angela, Gonzalez-Calle, V, Kyle, RA, O'Dwyer, Michael, Rajkumar, SV, Kortüm, KM, Keats, JJ, Fonseca, R, Stewart, A.Keith, Kuehl, WM, Braggio, Esteban, Bergsagel, PL
Externí odkaz:
http://hdl.handle.net/11250/2641175
Autor:
Hillengass, J, Moulopoulos, LA, Delorme, S, Koutoulidis, V, Mosebach, J, Hielscher, T, Drake, M., Rajkumar, SV, Oestergaard, B, Abildgaard, N, Hinge, M, Plesner, T, Suehara, Y, Matsue, K, Withofs, N, Caers, J, Waage, Anders, Goldschmidt, H, Dimopoulos, MA, Lentzsch, S, Durie, B, Terpos, E
Externí odkaz:
http://hdl.handle.net/11250/2503465
For decades, conventional skeletal survey (CSS) has been the standard imaging technique for multiple myeloma (MM). However, recently whole-body computed tomography (WBCT) has been implemented into the diagnostic criteria of MM. This analysis compares
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::45812544c55a83b106dbca61c990aacb
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108414
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3108414
Autor:
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Zangari M, Attal M, Belch A, Knop S, JoshuaD, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA, International Myeloma Working Group, CAVO, MICHELE
Publikováno v:
Leukemia, 22(2), 414-423. Nature Publishing Group
The incidence of venous thromboembolism (VTE) is more than 1 per thousand annually in the general population and increases further in cancer patients. The risk of VTE is higher in multiple myeloma (MM) patients who receive thalidomide or lenalidomide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d2a492348e0cd6ac57ff4524c01ba5a
https://pure.eur.nl/en/publications/2d5ab44b-5ea4-4e81-ae6d-847a25f1441e
https://pure.eur.nl/en/publications/2d5ab44b-5ea4-4e81-ae6d-847a25f1441e
Autor:
Stewart, Ak, Rajkumar, Sv, Dimopoulos, Ma, Masszi, T, Špička, I, Oriol, A, Hájek, R, Rosiñol, L, Siegel, Ds, Mihaylov, Gg, Goranova Marinova, V, Rajnics, P, Suvorov, A, Niesvizky, R, Jakubowiak, Aj, San Miguel JF, Ludwig, H, Wang, M, Maisnar, V, Minarik, J, Bensinger, Wi, Mateos, Mv, Ben Yehuda, D, Kukreti, V, Zojwalla, N, Tonda, Me, Yang, X, Xing, B, Moreau, P, Palumbo, A, Petrini, Mario, Aspire, Investigators
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b5f83b14e13f387639ec282aab0862
http://hdl.handle.net/11568/766303
http://hdl.handle.net/11568/766303